Do you want BuboFlash to help you learning these things? Or do you want to add or correct something? Click here to log in or create user.



Question
α-blocker doxazosin may be considered for its dual blood pressure–lowering effect and its effect on urinary frequency, its use as first-line therapy for persistent hypertension following lifestyle modification should be decided while considering its adverse effect profile [...]
Answer
(such as orthostatic hypotension) and its increased incidence of heart failure

Question
α-blocker doxazosin may be considered for its dual blood pressure–lowering effect and its effect on urinary frequency, its use as first-line therapy for persistent hypertension following lifestyle modification should be decided while considering its adverse effect profile [...]
Answer
?

Question
α-blocker doxazosin may be considered for its dual blood pressure–lowering effect and its effect on urinary frequency, its use as first-line therapy for persistent hypertension following lifestyle modification should be decided while considering its adverse effect profile [...]
Answer
(such as orthostatic hypotension) and its increased incidence of heart failure
If you want to change selection, open original toplevel document below and click on "Move attachment"

Parent (intermediate) annotation

Open it
al blood pressure–lowering effect and its effect on urinary frequency, its use as first-line therapy for persistent hypertension following lifestyle modification should be decided while considering its adverse effect profile <span>(such as orthostatic hypotension) and its increased incidence of heart failure<span><body><html>

Original toplevel document (pdf)

owner: ELBOMBARDO - (no access) - MKSAP_17.pdf, p3393

Summary

statusnot learnedmeasured difficulty37% [default]last interval [days]               
repetition number in this series0memorised on               scheduled repetition               
scheduled repetition interval               last repetition or drill

Details

No repetitions


Discussion

Do you want to join discussion? Click here to log in or create user.